The Reachable project from Conor Walsh's lab is a wearable shoulder device that assists patients with upper limb disability. Stroke survivor and collaborator, Julie Hahnke, shares her experience working with the research team, using the current prototype, and her hopes for how this technology could improve the physical therapy outcomes of stroke patients and others suffering from upper limb disability. Kristin Nuckols Patrick Slade #WearableRobotics #Robotics #StrokeRecovery
Wyss Institute at Harvard University
Biotechnology Research
Boston, MA 54,586 followers
About us
At the Wyss Institute, we leverage recent insights into how Nature builds, controls and manufactures to develop new engineering innovations - a new field of research we call Biologically Inspired Engineering. Our scientists, engineers and clinicians, who come from Harvard's Schools of Medicine, Engineering, Arts & Sciences, Design, and Education as well as 12 collaborating academic institutions and hospitals, work alongside staff with industrial experience in product development to engineer transformative solutions to some of the world’s greatest problems. By emulating biological principles of self assembly, organization and regulation, we are developing disruptive technology solutions for healthcare, energy, architecture, robotics, and manufacturing, which are translated into commercial products and therapies through formation of new startups and corporate alliances.
- Website
-
http://wyss.harvard.edu
External link for Wyss Institute at Harvard University
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Boston, MA
- Type
- Nonprofit
- Specialties
- Robotics, Bioengineering, Microfluidics, Medicine, Materials Science, Medical Devices, Synthetic Biology, Cell biology, Tissue engineering, Cancer research, Molecular engineering, Organ Engineering, Genome Editing, Molecular Robotics, and Immunomaterials
Locations
-
Primary
201 Brookline Ave.
Boston, MA 02215, US
Employees at Wyss Institute at Harvard University
-
Gangadhar Jogikalmath
Co-Founder Return To Vendor (RTV)
-
Ayis Antoniou
Entrepreneur/mentor/experienced, impactful, innovative leader/strategic advisor looking to connect with early-stage companies in bio-tech
-
James Gorman, M.D., Ph.D.
-
Samir Mitragotri
Professor @ Harvard University | Hiller Professor of Bioengineering | Hansjorg Wyss Professor of Biologically Inspired Engineering | Wyss Institute
Updates
-
July is Plastic Free Month. While individuals can do their best to reduce their dependence on single-use plastic, we still need to figure out what to do with existing pollution. Wyss startup Breaking is a plastic degradation and synthetic biology company gestated at Colossal Biosciences. Their microbes can break down plastic and could be globally deployed to decompose waste. #PlasticFreeMonth #PlasticPollution https://lnkd.in/eyYqB-hw
-
Did you know that 90% of diagnosed cancers form solid tumors? With the Wyss' Metabolically Labeled CAR-T Cells, we can better target cancer cells buried deep in tumor masses. Learn more: https://lnkd.in/eUWVa6F5 #CancerResearch #Immunotherapy #Threapeutics
-
At the Wyss, we aim to create an environment where everyone feels safe, heard, and trusted. Our success is dependent on our caring for each other, and collective enthusiasm for the effort of every team member, regardless of position, background, or tenure. We treat our equipment, offices, and labs with great care. If this sounds like the type of environment for you, check out our open roles: https://lnkd.in/eKYHdC2p #Hiring #STEMJobs #ResearchJobs
-
A mouse is not a human, and dialysis is not a kidney. Researchers from Sangeeta Bhatia, Christopher Chen, David Mooney, and Jennifer Lewis' labs are all part of the Wellcome Leap initiative. As part of the HOPE program, they worked to pioneer new solutions to the organ donor shortage and create better platforms to predict human immune responses to drugs. Take a glimpse into the stories of various researchers working as part of this effort. Together, we're challenging the notion of what's possible to achieve. https://lnkd.in/exesscfr #WellcomeLeap #Collaboration #OrganDonorShortage #KidneyDisease
-
A collaborative Wyss team, supported by the first agreement awarded to researchers at Harvard University by the Advanced Research Projects Agency for Health (ARPA-H), is embarking on its ambitious journey of developing a disease-agnostic novel RNA therapeutic. Natalie Artzi and Donald Ingber, along with Kenneth Carlson and William Shih, and the help of Wyss startup EnPlusOne Biosciences will be combining a newly discovered Duplex RNA, which safely and naturally stimulates the innate immune system, with innovative drug delivery methods. This new immunotherapy has the potential to treat diverse diseases, including different types of cancer and infectious diseases. #Grant #Therapeutics #Cancer #InfectiousDisease https://lnkd.in/ePb2w8AJ
-
DoriVac is a personalized immunotherapy platform harnessing DNA nanotechnology to co-deliver drug combinations with nanoscale precision. It's applicable to cancer, autoimmune diseases, and infectious diseases. #CancerVaccine #Nanotechnology https://lnkd.in/eXJ7PQ_X
DoriVac: Boosting Antigen-specific Immune Responses with DNA Origami-Based Vaccines
https://wyss.harvard.edu
-
Wyss researchers have discovered a new class of immunostimulatory double-stranded RNAs (dsRNAs) that produce pan-antiviral activity by inducing the expression of multiple types of interferons. These dsRNAs can effectively inhibit infection of human lung cells by a wide range of viruses including SARS-CoV-2, influenza A, and even common cold viruses, and reduced SARS-CoV-2 infection in a mouse COVID model by up to five orders of magnitude. #Immunotherapy #Therapeutics #InfectiousDisease https://lnkd.in/ec3pGbd
Broad-Spectrum RNA Therapeutic for Treatment of COVID-19 and Influenza
https://wyss.harvard.edu
-
RNA drugs are the next frontier of medicine, but manufacturing them requires an expensive and labor-intensive process that limits production and produces metric tons of toxic chemical waste. In a new paper published today in Nature Biochemical Engineering, a team of researchers from the Wyss Institute and Harvard Medical School report a new, enzyme-based RNA synthesis method that can produce strands of RNA with both natural and modified nucleotides without the environmental hazards. This approach enables the rapid scale-up needed to meet the growing demand for RNA therapeutics, and is being commercialized by Wyss startup EnPlusOne Biosciences. Northpond Ventures Jonathan Rittichier Daniel Wiegand #Oligonucleotides #RNA #Therapeutics #StartupNews https://lnkd.in/eqc3rXqp
-
"Because science and technology development are progressing at an ever-higher speed, and are globalizing rapidly, real-time collaboration between researchers and ethicists becomes so vital." Jeantine E. Lunshof In a recent paper in Nature Methods, she and Julia Rijssenbeek describe their model for collaboration between scientists and ethicists and how it benefits the research process and results. Learn more: https://bit.ly/3LiwEdd